1. Home
  2. NTAP vs UTHR Comparison

NTAP vs UTHR Comparison

Compare NTAP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetApp Inc.

NTAP

NetApp Inc.

HOLD

Current Price

$111.81

Market Cap

20.5B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$578.48

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTAP
UTHR
Founded
1992
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5B
25.1B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
NTAP
UTHR
Price
$111.81
$578.48
Analyst Decision
Hold
Buy
Analyst Count
13
14
Target Price
$116.58
$567.57
AVG Volume (30 Days)
1.8M
544.7K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
1.86%
N/A
EPS Growth
22.46
13.07
EPS
4.32
27.86
Revenue
$6,233,200,000.00
$1,483,300,000.00
Revenue This Year
$6.22
$6.39
Revenue Next Year
$4.91
$14.18
P/E Ratio
$25.87
$20.62
Revenue Growth
N/A
2.38
52 Week Low
$85.12
$272.18
52 Week High
$126.66
$607.89

Technical Indicators

Market Signals
Indicator
NTAP
UTHR
Relative Strength Index (RSI) 68.91 58.16
Support Level $101.76 $464.92
Resistance Level $121.90 $607.89
Average True Range (ATR) 3.11 14.25
MACD 1.39 -2.04
Stochastic Oscillator 89.23 60.71

Price Performance

Historical Comparison
NTAP
UTHR

About NTAP NetApp Inc.

NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of the cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services. Geographically, the company generates the majority of its revenue from the United States, Canada and Latin America (Americas).

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: